Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546–593

Article  CAS  PubMed  Google Scholar 

Novo Nordisk (2020) Saxenda remains world’s top obesity treatment. Retrieved March 12, 2021, from https://www.koreabiomed.com/news/articleView.html?idxno=7768. Accessed 12 Apr 2024

Singh PM, Kashyap L (2013) Post-operative severe hypokalemia mimicking myocardial ischemia. J Anaesthesiol Clin Pharmacol 29(4):567–568. https://doi.org/10.4103/0970-9185.119146

Article  PubMed  PubMed Central  Google Scholar 

Watson E, Jonker DM, Jacobsen LV, Ingwersen SH (2010) Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol 50:886–894. https://doi.org/10.1177/0091270009354996

Article  CAS  PubMed  Google Scholar 

He F, Chen W, Xu W, Liu D, Xiao Z, Tang Y, Chen Y (2023) Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metabol 25(3):664–674. https://doi.org/10.1111/dom.14908